Press release content from Globe Newswire. The AP news staff was not involved in its creation.
FDA Clears IND Application for Passage Bio’s Gene Therapy Candidate PBKR03 for Treatment of .
Passage BioFebruary 8, 2021 GMT
- Phase 1/2 trial expected to commence in first half of 2021
- Company has three INDs cleared for rare monogenic CNS disorders
PHILADELPHIA, Feb. 08, 2021 (GLOBE NEWSWIRE) Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for PBKR03, an adeno-associated virus (AAV)-delivery gene therapy being studied for the treatment of early infantile Krabbe disease (Globoid Cell Leukodystrophy). Currently, there are no approved disease-modifying therapies available for Krabbe disease, a rare lysosomal storage disease that most often
Sensei Biotherapeutics Announces Pricing of Upsized Initial Public Offering
February 03, 2021 20:44 ET | Source: Sensei Biotherapeutics Sensei Biotherapeutics Gaithersburg, Maryland, UNITED STATES
BOSTON and ROCKVILLE, Md., Feb. 03, 2021 (GLOBE NEWSWIRE) Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the pricing of its upsized initial public offering of 7,000,052 shares of common stock at a public offering price of $19.00 per share. The gross proceeds to Sensei from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Sensei, are expected to be approximately $133.0 million. All of the shares are being offered by Sensei and are expected to begin trading on The Nasdaq Global Market on February 4, 2021 under the ticker symbol “SNSE.” In addition, Sen
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 .
Ayala PharmaceuticalsJanuary 28, 2021 GMT
REHOVOT, Israel and WILMINGTON, Del., Jan. 28, 2021 (GLOBE NEWSWIRE) Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced the first patient dosed in the Phase 2 TENACITY clinical trial of its potent, selective small molecule AL101, for the treatment of patients with Notch-activated recurrent or metastatic (R/M) triple negative breast cancer (TNBC).
Passage Bio Announces Pricing of Public Offering forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
4D pharma plc: 4D pharma to Participate in 5th Microbiome Movement Drug Development Summit Europe
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) a novel class of drug derived from the microbiome, today announced its participation in the Microbiome Movement Drug Development Summit Europe, including the Plenary Session, Microbiome Leaders Industry Review Panel.
Plenary Session: European Microbiome Leaders Panel Discussion on Thursday, January 28, 2021 at 8:00am GMT (3:00am ET) with Chief Scientific Officer, Dr. Alex Stevenson, Ph.D.
Clinical Trial Design and Evaluating PK/PD Session: MicroRx and Single Strain Live Biotherapeutics: Proof of Concept Clinical Data and Future Considerations on Thursday, January 28, 2021 at 11:30pm GMT (6:30am ET) with Research Director, Dr. Imke Mulder